Scholarlink

Background <p>Multidrug-resistant (MDR) <i>Klebsiella pneumoniae</i> poses a critical threat in oncology intensive care units (ICUs), particularly in low- and middle-income countries like Egypt, where immunocompromised patients are at high risk from invasive procedures. This study aimed to characterize antimicrobial resistance patterns and molecular features of MDR <i>K. pneumoniae</i> isolates and to explore clinical and genetic markers associated with resistance burden.</p> Methods <p>Fifty <i>K. pneumoniae</i> isolates were recovered from cancer patients at Shefa Al Orman Oncology Hospital (Luxor, Egypt). Susceptibility testing was performed using VITEK® 2. Resistance genes (<i>OmpK35, QnrB, AcrAB, OqxA</i>, and <i>Sul2</i>) were detected via PCR. Resistance burden was quantified as a resistance score (R-score) and analyzed against clinical and genetic variables using non-parametric tests and regression models.</p> Results <p>All isolates (100%) were resistant to β-lactams. High resistance rates were observed for carbapenems (78–84%), fluoroquinolones (84%), aminoglycosides (76–80%), and trimethoprim–sulfamethoxazole (86%), while tetracycline (40%) and tigecycline (10%) showed lower resistance. Genetic analysis revealed <i>Sul2</i> (100%), <i>OmpK35</i> (94%), <i>OqxA</i> (92%), <i>QnrB</i> (90%), and <i>AcrAB</i> (68%). Prior hospitalization and antibiotic use within three months were the only independent risk factors for higher R-scores (p = 0.041). Patient mortality reached 46%.</p> Conclusion <p>MDR <i>K. pneumoniae</i> in oncology ICUs shows extensive resistance and multiple genetic associations. Prior healthcare exposure significantly increases resistance burden, emphasizing the urgent need for stringent antimicrobial stewardship and targeted infection control measures.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Multidrug-resistant Klebsiella pneumoniae in oncology intensive care units: selected genetic markers and clinical predictors

  • 期刊论文

  • 发表日期：

    2026年4月21日

查看全文
  • Aya El Nahas,
  • Ahmed O. El-Gendy,
  • Mona Wassef,
  • Fatma Molham

摘要

Background

Multidrug-resistant (MDR) Klebsiella pneumoniae poses a critical threat in oncology intensive care units (ICUs), particularly in low- and middle-income countries like Egypt, where immunocompromised patients are at high risk from invasive procedures. This study aimed to characterize antimicrobial resistance patterns and molecular features of MDR K. pneumoniae isolates and to explore clinical and genetic markers associated with resistance burden.

Methods

Fifty K. pneumoniae isolates were recovered from cancer patients at Shefa Al Orman Oncology Hospital (Luxor, Egypt). Susceptibility testing was performed using VITEK® 2. Resistance genes (OmpK35, QnrB, AcrAB, OqxA, and Sul2) were detected via PCR. Resistance burden was quantified as a resistance score (R-score) and analyzed against clinical and genetic variables using non-parametric tests and regression models.

Results

All isolates (100%) were resistant to β-lactams. High resistance rates were observed for carbapenems (78–84%), fluoroquinolones (84%), aminoglycosides (76–80%), and trimethoprim–sulfamethoxazole (86%), while tetracycline (40%) and tigecycline (10%) showed lower resistance. Genetic analysis revealed Sul2 (100%), OmpK35 (94%), OqxA (92%), QnrB (90%), and AcrAB (68%). Prior hospitalization and antibiotic use within three months were the only independent risk factors for higher R-scores (p = 0.041). Patient mortality reached 46%.

Conclusion

MDR K. pneumoniae in oncology ICUs shows extensive resistance and multiple genetic associations. Prior healthcare exposure significantly increases resistance burden, emphasizing the urgent need for stringent antimicrobial stewardship and targeted infection control measures.